]> Melendez QM, Wooten CJ, Krishnaji ST, et al. Volume 3 Issue 1 2581-4745 10.31531/2581-4745.1000123 High levels of cholesterol especially as lowdensity lipoprotein LDL are a wellknown risk factor for atheroscleroticrelated diseases The key atherogenic property of LDL is its ability to form atherosclerotic plaque Proprotein convertase subtilisinkexin9 PCSK9 is an indirect regulator of plasma LDL levels by controlling the number of LDL receptor molecules expressed at the plasma membrane especially in the liver Herein we performed a combination of affinity chromatography mass spectrometry analysis and identification and gene expression studies to identify proteins that interact with PCSK9 Through these studies we identified three proteins alpha1antitrypsin A1AT alpha1microglobulinbikunin precursor AMBP and apolipoprotein H APOH expressed by C3A cells that interact with PCSK9 The expression levels of A1AT and APOH increased in cells treated with MITO medium a condition previously shown to affect the function of PCSK9 as compared to treating with Regular control medium However AMBP expression did not change in response to the treatments Additional studies are required to determine which of these proteins can modulate the expressionfunction of PCSK9 The identification of endogenous modulators of PCSK9s function could lead to the development of novel diagnostic tests or treatment options for patients suffering hypercholesterolemia in combination with other chronic metabolic diseases All Published Work is Licensed under a creative commons attribution 4.0 international license 2024